Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes

The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.

Inclusion Criteria:

T2D Cohort:

• A clinical diagnosis of T2D ≥ 1 year
• HbA1c ≥ 6.5% (pre-index date)
• Initiated semaglutide or other AHA(s) before January 1st, 2023*
• Seen by an LMC endocrinologist in the last 18 months as of the query date
• ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
• Informed data consent for their medical record data to be used for research purposes

Obesity Cohort:

• 18 years or older
• BMI ≥ 27 kg/m2
• HbA1c < 6.5% (pre-index date)
• Initiated semaglutide before January 1st, 2023*
• Seen by an LMC endocrinologist in the last 18 months as of the query date
• ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
• Informed data consent for their medical record data to be used for research purposes

Exclusion Criteria:

• Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
• Clinical diagnosis of T2D (obesity cohort only)
• Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
• Documented history or family history of medullary thyroid carcinoma
• Participation in a research study with an Investigational Product
• eGFR < 15 mL/min/1.73m2 at index date
• Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
• Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)